|
|
Volumn 21, Issue 10 Suppl, 2003, Pages
|
|
Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ENZYME INHIBITOR;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
ERBB2 PROTEIN, HUMAN;
FARNESYL TRANS TRANSFERASE;
MAMMALIAN TARGET OF RAPAMYCIN;
MONOCLONAL ANTIBODY;
NEW DRUG;
PHOSPHATIDYLINOSITOL 3 KINASE;
PROTEIN KINASE;
PROTEIN KINASE INHIBITOR;
RAS PROTEIN;
ANIMAL;
DRUG ANTAGONISM;
DRUG DESIGN;
DRUG EFFECT;
DRUG SCREENING;
ENZYMOLOGY;
FEMALE;
FEMALE GENITAL TRACT TUMOR;
HUMAN;
IMMUNOLOGY;
MALE;
METABOLISM;
METHODOLOGY;
NEOPLASM;
PATIENT SELECTION;
REVIEW;
SIGNAL TRANSDUCTION;
TREATMENT OUTCOME;
1-PHOSPHATIDYLINOSITOL 3-KINASE;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
DRUG DESIGN;
DRUG EVALUATION, PRECLINICAL;
DRUGS, INVESTIGATIONAL;
ENZYME INHIBITORS;
FARNESYLTRANSTRANSFERASE;
FEMALE;
GENITAL NEOPLASMS, FEMALE;
HUMANS;
MALE;
MAP KINASE SIGNALING SYSTEM;
NEOPLASMS;
PATIENT SELECTION;
PROTEIN KINASE INHIBITORS;
PROTEIN KINASES;
RAS PROTEINS;
RECEPTOR, ERBB-2;
SIGNAL TRANSDUCTION;
TREATMENT OUTCOME;
MLCS;
MLOWN;
|
|
EID: 0348015959
PISSN: None
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/jco.2003.01.146 Document Type: Review |
|
Times cited : (10)
|
|
References (98)
|
